|
|
|
|
|||||
|
|
|
Roivant Sciences Ltd (NASDAQ:ROIV) is one of the Best Mid Cap Growth Stocks to Buy According to Hedge Funds. On August 11, Roivant Sciences Ltd (NASDAQ:ROIV) reported its financial and business update for the fiscal first quarter of 2025.
The company reported several positive business updates, including the Brepocitinib VALOR Phase 3 study for dermatomyositis remaining on track for topline data in the second half of 2025. Moreover, Immunovant, which is a subsidiary of Roivant Sciences Ltd (NASDAQ:ROIV), started new registrational trials for IMVT-1402 in Graves’ disease and Sjögren’s disease, with all other trials progressing well.
The company had $4.5 billion in cash and marketable securities as of June 30, 2025. Management believes this supports the cash runway into profitability.
Roivant Sciences Ltd (NASDAQ:ROIV) is a biopharmaceutical company that develops and commercializes innovative medicines by building focused subsidiary companies called Vants.
While we acknowledge the potential of ROIV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
| Aug-28 | |
| Aug-12 | |
| Aug-12 | |
| Aug-11 | |
| Aug-11 | |
| Aug-11 | |
| Aug-08 | |
| Aug-07 | |
| Aug-05 | |
| Jul-28 | |
| Jul-24 | |
| Jul-11 | |
| Jun-24 | |
| Jun-16 | |
| Jun-09 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite